Optomed Oyj Second Quarter 2024 Earnings: Misses Expectations

Optomed Oyj (HEL:OPTOMED) Second Quarter 2024 Results

Key Financial Results

• Revenue: €3.51m (down 6.1% from 2Q 2023).
• Net loss: €1.79m (loss widened by 37% from 2Q 2023).
• €0.10 loss per share (further deteriorated from €0.084 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Optomed Oyj Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 150%.

Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are down 16% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Optomed Oyj has 2 warning signs (and 1 which can't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.